1
|
Kerba M, Lourenco RDA, Sahgal A, Cardet RDF, Siva S, Ding K, Myrehaug SD, Masucci GL, Brundage M, Parulekar WR. An Economic Analysis of SC24 in Canada: A Randomized Study of SBRT Compared With Conventional Palliative RT for Spinal Metastases. Int J Radiat Oncol Biol Phys 2024; 119:1061-1068. [PMID: 38218455 DOI: 10.1016/j.ijrobp.2023.12.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2022] [Revised: 12/19/2023] [Accepted: 12/31/2023] [Indexed: 01/15/2024]
Abstract
PURPOSE The Canadian Cancer Trials Group (CCTG) Symptom Control 24 protocol (SC.24) was a multicenter randomized controlled phase 2/3 trial conducted in Canada and Australia. Patients with painful spinal metastases were randomized to either 24 Gy/2 stereotactic body radiation therapy (SBRT) or 20 Gy/5 conventional external beam radiation therapy (CRT). The study met its primary endpoint and demonstrated superior complete pain response rates at 3 months following SBRT (35%) versus CRT (14%). SBRT planning and delivery is resource intensive. Given its benefits in SC.24, we performed an economic analysis to determine the incremental cost-effectiveness of SBRT compared with CRT. METHODS AND MATERIALS The trial recruited 229 patients. Cost-effectiveness was assessed using a Markov model taking into account observed survival, treatments costs, retreatment, and quality of life over the lifetime of the patient. The EORTC-QLU-C10D was used to determine quality of life values. Transition probabilities for outcomes were from available patient data. Health system costs were from the Canadian health care perspective and were based on 2021 Canadian dollars (CAD). The incremental cost-effectiveness ratio (ICER) was expressed as the ratio of incremental cost to quality-adjusted life years (QALY). The impact of parameter uncertainty was investigated using deterministic and probabilistic sensitivity analyses. RESULTS The base case for SBRT compared with CRT had an ICER of $9,040CAD per QALY gained. Sensitivity analyses demonstrated that the ICER was most sensitive to variations in the utility assigned to "No local failure" ($5,457CAD to $241,051CAD per QALY), adopting low and high estimates of utility and the cost of the SBRT (ICERs ranging from $7345-$123,361CAD per QALY). It was more robust to variations in assumptions around survival and response rate. CONCLUSIONS SBRT is associated with higher upfront costs than CRT. The ICER shows that, within the Canadian health care system, SBRT with 2 fractions is likely to be more cost-effective than CRT.
Collapse
Affiliation(s)
- Marc Kerba
- Department of Radiation Oncology, University of Calgary, Calgary, Alberta, Canada.
| | - Richard De Abreu Lourenco
- Centre for Health Economics Research and Evaluation, University of Technology Sydney, Ultimo, New South Wales, Australia
| | - Arjun Sahgal
- Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada
| | - Rafael De Feria Cardet
- Centre for Health Economics Research and Evaluation, University of Technology Sydney, Ultimo, New South Wales, Australia
| | - Shankar Siva
- Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Victoria, Australia
| | - Keyue Ding
- Canadian Clinical Trials Group, Queen's University, Kingston, Ontario, Canada.
| | - Sten D Myrehaug
- Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada
| | - Giuseppina L Masucci
- Department of Radiation Oncology, Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
| | - Michael Brundage
- Department of Cancer Care and Epidemiology, Queens's University, Kingston, Ontario, Canada
| | - Wendy R Parulekar
- Canadian Clinical Trials Group, Queen's University, Kingston, Ontario, Canada
| |
Collapse
|
2
|
Costs of Newly Funded Proton Therapy Using Time-Driven Activity-Based Costing in The Netherlands. Cancers (Basel) 2023; 15:cancers15020516. [PMID: 36672465 PMCID: PMC9856812 DOI: 10.3390/cancers15020516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2022] [Revised: 01/08/2023] [Accepted: 01/11/2023] [Indexed: 01/18/2023] Open
Abstract
BACKGROUND Proton therapy (PT) has characteristics that enable the sparing of healthy, non-cancerous tissue surrounding the radiotherapy target volume better from radiation doses than conventional radiotherapy for patients with cancer. While this innovation entails investment costs, the information about the treatment costs per patient, especially during the start-up phase, is limited. This study aims to calculate the costs of PT at a single center during the start-up phase in the Netherlands. METHODS The cost of PT per patient was estimated for the treatment indications, head and neck cancer, breast cancer, brain cancer, thorax cancer, chordoma and eye melanoma. A time-driven activity-based costing analysis (TDABC), a methodology that calculates the costs of consumed healthcare resources by a patient, was conducted in a newly established PT center in the Netherlands (HPTC). Both direct (e.g., the human resource costs for medical staff) and indirect costs (e.g., the operating/interest costs, indirect human resource costs and depreciation costs) were included. A scenario analysis was conducted for short-term (2021), middle-term (till 2024) and long-term (after 2024) predicted patient numbers in the PT center. RESULTS The total cost of PT in 2020 at the center varied between EUR 12,062 for an eye melanoma course and EUR 89,716 for a head and neck course. Overall, indirect costs were the largest cost component. The high indirect costs implied the potential of the scale of economics; according to our estimation, the treatment cost could be reduced to 35% of the current cost when maximum treatment capacity is achieved. CONCLUSION This study estimated the PT cost delivered in a newly operated treatment center. Scenario analysis for increased patient numbers revealed the potential for cost reductions. Nevertheless, to have an estimation that reflects the matured cost of PT which could be used in cost-effectiveness analysis, a follow-up study assessing the full-fledged situation is recommended.
Collapse
|
3
|
Defourny N, Perrier L, Borras JM, Coffey M, Corral J, Hoozée S, Loon JV, Grau C, Lievens Y. National costs and resource requirements of external beam radiotherapy: A time-driven activity-based costing model from the ESTRO-HERO project. Radiother Oncol 2019; 138:187-194. [DOI: 10.1016/j.radonc.2019.06.015] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2018] [Revised: 06/11/2019] [Accepted: 06/11/2019] [Indexed: 10/26/2022]
|
4
|
Van Dyk J, Zubizarreta E, Lievens Y. Cost evaluation to optimise radiation therapy implementation in different income settings: A time-driven activity-based analysis. Radiother Oncol 2017; 125:178-185. [PMID: 28947098 DOI: 10.1016/j.radonc.2017.08.021] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2017] [Revised: 08/12/2017] [Accepted: 08/25/2017] [Indexed: 10/18/2022]
Abstract
BACKGROUND With increasing recognition of growing cancer incidence globally, efficient means of expanding radiotherapy capacity is imperative, and understanding the factors impacting human and financial needs is valuable. MATERIALS AND METHODS A time-driven activity-based costing analysis was performed, using a base case of 2-machine departments, with defined cost inputs and operating parameters. Four income groups were analysed, ranging from low to high income. Scenario analyses included department size, operating hours, fractionation, treatment complexity, efficiency, and centralised versus decentralised care. RESULTS The base case cost/course is US$5,368 in HICs, US$2,028 in LICs; the annual operating cost is US$4,595,000 and US$1,736,000, respectively. Economies of scale show cost/course decreasing with increasing department size, mainly related to the equipment cost and most prominent up to 3 linacs. The cost in HICs is two or three times as high as in U-MICs or LICs, respectively. Decreasing operating hours below 8h/day has a dramatic impact on the cost/course. IMRT increases the cost/course by 22%. Centralising preparatory activities has a moderate impact on the costs. CONCLUSIONS The results indicate trends that are useful for optimising local and regional circumstances. This methodology can provide input into a uniform and accepted approach to evaluating the cost of radiotherapy.
Collapse
Affiliation(s)
| | | | - Yolande Lievens
- Radiation Oncology Department, Ghent University Hospital and Ghent University, Belgium
| |
Collapse
|
5
|
Yong JHE, McGowan T, Redmond-Misner R, Beca J, Warde P, Gutierrez E, Hoch JS. Estimating the costs of intensity-modulated and 3-dimensional conformal radiotherapy in Ontario. ACTA ACUST UNITED AC 2016; 23:e228-38. [PMID: 27330359 DOI: 10.3747/co.23.2998] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
BACKGROUND Radiotherapy is a common treatment for many cancers, but up-to-date estimates of the costs of radiotherapy are lacking. In the present study, we estimated the unit costs of intensity-modulated radiotherapy (imrt) and 3-dimensional conformal radiotherapy (3D-crt) in Ontario. METHODS An activity-based costing model was developed to estimate the costs of imrt and 3D-crt in prostate cancer. It included the costs of equipment, staff, and supporting infrastructure. The framework was subsequently adapted to estimate the costs of radiotherapy in breast cancer and head-and-neck cancer. We also tested various scenarios by varying the program maturity and the use of volumetric modulated arc therapy (vmat) alongside imrt. RESULTS From the perspective of the health care system, treating prostate cancer with imrt and 3D-crt respectively cost $12,834 and $12,453 per patient. The cost of radiotherapy ranged from $5,270 to $14,155 and was sensitive to analytic perspective, radiation technique, and disease site. Cases of head-and-neck cancer were the most costly, being driven by treatment complexity and fractions per treatment. Although imrt was more costly than 3D-crt, its cost will likely decline over time as programs mature and vmat is incorporated. CONCLUSIONS Our costing model can be modified to estimate the costs of 3D-crt and imrt for various disease sites and settings. The results demonstrate the important role of capital costs in studies of radiotherapy cost from a health system perspective, which our model can accommodate. In addition, our study established the need for future analyses of imrt cost to consider how vmat affects time consumption.
Collapse
Affiliation(s)
- J H E Yong
- St. Michael's Hospital, Toronto, ON;; Cancer Care Ontario, Toronto, ON;; Canadian Centre for Applied Research in Cancer Control, Toronto, ON
| | - T McGowan
- Department of Radiation Oncology, Faculty of Medicine, University of Toronto, Toronto, ON;; The Cancer Centre Bahamas, Nassau, Bahamas;; The Cancer Centre Eastern Caribbean, St. John's, Antigua
| | - R Redmond-Misner
- St. Michael's Hospital, Toronto, ON;; Cancer Care Ontario, Toronto, ON;; Canadian Centre for Applied Research in Cancer Control, Toronto, ON
| | - J Beca
- St. Michael's Hospital, Toronto, ON;; Cancer Care Ontario, Toronto, ON;; Canadian Centre for Applied Research in Cancer Control, Toronto, ON
| | - P Warde
- Canadian Centre for Applied Research in Cancer Control, Toronto, ON;; Department of Radiation Oncology, Faculty of Medicine, University of Toronto, Toronto, ON;; Princess Margaret Hospital, University of Toronto, Toronto, ON
| | | | - J S Hoch
- St. Michael's Hospital, Toronto, ON;; Cancer Care Ontario, Toronto, ON;; Canadian Centre for Applied Research in Cancer Control, Toronto, ON;; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON
| |
Collapse
|
6
|
Han K, Yap ML, Yong JHE, Mittmann N, Hoch JS, Fyles AW, Warde P, Gutierrez E, Lymberiou T, Foxcroft S, Liu FF. Omission of Breast Radiotherapy in Low-risk Luminal A Breast Cancer: Impact on Health Care Costs. Clin Oncol (R Coll Radiol) 2016; 28:587-93. [PMID: 27139262 DOI: 10.1016/j.clon.2016.04.003] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2016] [Revised: 02/29/2016] [Accepted: 03/03/2016] [Indexed: 01/08/2023]
Abstract
AIMS The economic burden of cancer care is substantial, including steep increases in costs for breast cancer management. There is mounting evidence that women age ≥ 60 years with grade I/II T1N0 luminal A (ER/PR+, HER2- and Ki67 ≤ 13%) breast cancer have such low local recurrence rates that adjuvant breast radiotherapy might offer limited value. We aimed to determine the total savings to a publicly funded health care system should omission of radiotherapy become standard of care for these patients. MATERIALS AND METHODS The number of women aged ≥ 60 years who received adjuvant radiotherapy for T1N0 ER+ HER2- breast cancer in Ontario was obtained from the provincial cancer agency. The cost of adjuvant breast radiotherapy was estimated through activity-based costing from a public payer perspective. The total saving was calculated by multiplying the estimated number of luminal A cases that received radiotherapy by the cost of radiotherapy minus Ki-67 testing. RESULTS In 2010, 748 women age ≥ 60 years underwent surgery for pT1N0 ER+ HER2- breast cancer; 539 (72%) underwent adjuvant radiotherapy, of whom 329 were estimated to be grade I/II luminal A subtype. The cost of adjuvant breast radiotherapy per case was estimated at $6135.85; the cost of Ki-67 at $114.71. This translated into an annual saving of about $2.0million if radiotherapy was omitted for all low-risk luminal A breast cancer patients in Ontario and $5.1million across Canada. CONCLUSION There will be significant savings to the health care system should omission of radiotherapy become standard practice for women with low-risk luminal A breast cancer.
Collapse
Affiliation(s)
- K Han
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada
| | - M L Yap
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
| | - J H E Yong
- St. Michael's Hospital, Toronto, Ontario, Canada; Cancer Care Ontario, Toronto, Ontario, Canada
| | - N Mittmann
- HOPE Research Centre, Toronto, Ontario, Canada; Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada
| | - J S Hoch
- St. Michael's Hospital, Toronto, Ontario, Canada; Cancer Care Ontario, Toronto, Ontario, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Institute of Clinical Evaluative Studies, Toronto, Ontario, Canada
| | - A W Fyles
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada
| | - P Warde
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada; Cancer Care Ontario, Toronto, Ontario, Canada
| | - E Gutierrez
- Cancer Care Ontario, Toronto, Ontario, Canada
| | - T Lymberiou
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
| | - S Foxcroft
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
| | - F F Liu
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
| |
Collapse
|
7
|
Olivotto IA, Soo J, Olson RA, Rowe L, French J, Jensen B, Pastuch A, Halperin R, Truong PT. Patient preferences for timing and access to radiation therapy. ACTA ACUST UNITED AC 2015; 22:279-86. [PMID: 26300666 DOI: 10.3747/co.22.2532] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
PURPOSE Patient preferences for radiation therapy (rt) access were investigated. METHODS Patients completing a course of rt at 6 centres received a 17-item survey that rated preferences for time of day; day of week; actual, ideal, and reasonable travel times for rt; and actual, ideal, and reasonable times between referral and first oncologic consultation. Patients receiving single-fraction rt or brachytherapy alone were excluded. RESULTS Of the respondents who returned surveys (n = 1053), 54% were women, and 74% had received more than 15 rt fractions. With respect to appointment times, 88% agreed or strongly agreed that rt between 08h00 and 16h30 was preferred; 14%-15% preferred 07h30-08h00 or 16h30-17h00; 10% preferred 17h00-18h00; and 6% or fewer preferred times before 07h30 or after 18h00. A preference not to receive rt before 07h30 or after 18h00 was expressed by 30% or more of the respondents. When days of the week were considered, 18% and 11% would have preferred to receive rt on a Saturday or Sunday respectively; 52% and 55% would have preferred not to receive rt on those days. A travel time of 1 hour or less for rt was reported by 82%, but 61% felt that a travel time of 1 hour or more was reasonable. A first consultation within 2 weeks of referral was felt to be ideal or reasonable by 88% and 73% of patients respectively. CONCLUSIONS An rt service designed to meet patient preferences would make most capacity available between 08h00 and 16h30 on weekdays and provide 10%-20% of rt capacity on weekends and during 07h30-08h00 and 16h30-18h00 on weekdays. Approximately 80%, but not all, of the responding patients preferred a 2-week or shorter interval between referral and first oncologic consultation.
Collapse
Affiliation(s)
- I A Olivotto
- BC Cancer Agency, Radiation Therapy Program, Vancouver, Prince George, Surrey, Victoria, Abbotsford, and Kelowna, BC; ; University of British Columbia, Division of Radiation Oncology and Developmental Radiotherapeutics, Vancouver, Prince George, Kelowna, and Victoria, BC; ; University of Calgary, Calgary, AB
| | - J Soo
- BC Cancer Agency, Radiation Therapy Program, Vancouver, Prince George, Surrey, Victoria, Abbotsford, and Kelowna, BC
| | - R A Olson
- BC Cancer Agency, Radiation Therapy Program, Vancouver, Prince George, Surrey, Victoria, Abbotsford, and Kelowna, BC; ; University of British Columbia, Division of Radiation Oncology and Developmental Radiotherapeutics, Vancouver, Prince George, Kelowna, and Victoria, BC
| | - L Rowe
- BC Cancer Agency, Radiation Therapy Program, Vancouver, Prince George, Surrey, Victoria, Abbotsford, and Kelowna, BC
| | - J French
- BC Cancer Agency, Radiation Therapy Program, Vancouver, Prince George, Surrey, Victoria, Abbotsford, and Kelowna, BC
| | - B Jensen
- BC Cancer Agency, Radiation Therapy Program, Vancouver, Prince George, Surrey, Victoria, Abbotsford, and Kelowna, BC
| | - A Pastuch
- BC Cancer Agency, Radiation Therapy Program, Vancouver, Prince George, Surrey, Victoria, Abbotsford, and Kelowna, BC
| | - R Halperin
- BC Cancer Agency, Radiation Therapy Program, Vancouver, Prince George, Surrey, Victoria, Abbotsford, and Kelowna, BC; ; University of British Columbia, Division of Radiation Oncology and Developmental Radiotherapeutics, Vancouver, Prince George, Kelowna, and Victoria, BC
| | - P T Truong
- BC Cancer Agency, Radiation Therapy Program, Vancouver, Prince George, Surrey, Victoria, Abbotsford, and Kelowna, BC; ; University of British Columbia, Division of Radiation Oncology and Developmental Radiotherapeutics, Vancouver, Prince George, Kelowna, and Victoria, BC
| |
Collapse
|
8
|
Lievens Y, Borras JM, Grau C. Cost calculation: a necessary step towards widespread adoption of advanced radiotherapy technology. Acta Oncol 2015. [PMID: 26198650 DOI: 10.3109/0284186x.2015.1066932] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Radiotherapy costs are an often underestimated component of the economic assessment of new radiotherapy treatments and technologies. That the radiotherapy budget only consumes a finite part of the total cancer and healthcare budget does not relieve us from our responsibility to balance the extra costs to the additional benefits of new, more advanced, but typically also more expensive treatments we want to deliver. Yet, in contrast to what is the case for oncology drugs, literature evidence remains limited, as well for economic evaluations comparing new radiotherapy interventions as for cost calculation studies. Even more cumbersome, the available costing studies in the field of radiotherapy fail to accurately capture the real costs of our treatments due to the large variation in cost inputs, in scope of the analysis, in costing methodology. And this is not trivial. Accurate resource cost accounting lays the basis for the further steps in health technology assessment leading to radiotherapy investments and reimbursement, at the local, the national and the worldwide level. In the current paper we review some evidence from the existing costing literature and discuss how such data can be used to support reimbursement setting and investment cases for new radiotherapy equipment and infrastructure.
Collapse
Affiliation(s)
- Yolande Lievens
- a Radiation Oncology Department, Ghent University Hospital , Ghent , Belgium
| | | | - Cai Grau
- c Department of Oncology , Aarhus University Hospital , Aarhus , Denmark
| |
Collapse
|
9
|
Hanly P, Céilleachair AÓ, Skally M, O'Neill C, Sharp L. Direct costs of radiotherapy for rectal cancer: a microcosting study. BMC Health Serv Res 2015; 15:184. [PMID: 25934169 PMCID: PMC4494796 DOI: 10.1186/s12913-015-0845-9] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2014] [Accepted: 04/24/2015] [Indexed: 11/10/2022] Open
Abstract
Background Radiotherapy provides significant benefits in terms of reducing risk of local recurrence and death from rectal cancer. Despite this, up-to-date cost estimates for radiotherapy are lacking, potentially inhibiting policy and decision-making. Our objective was to generate an up-to-date estimate of the cost of traditional radiotherapy for rectal cancer and model the impact of a range of potential efficiency improvements. Methods Microcosting methods were used to estimate total direct radiotherapy costs for long- (assumed at 45-50 Gy in 25 daily fractions over a 5 week period) and short-courses (assumed at 25 Gy in 5 daily fractions over a one week period). Following interviews and on-site visits to radiotherapy departments in two designated cancer centers, a radiotherapy care pathway for a typical rectal cancer patient was developed. Total direct costs were derived by applying fixed and variable unit costs to resource use within each care phase. Costs included labor, capital, consumables and overheads. Sensitivity analyses were performed. Results Radiotherapy treatment was estimated to cost between €2,080 (5-fraction course) and €3,609 (25-fraction course) for an average patient in 2012. Costs were highest in the treatment planning phase for the short-course (€1,217; 58% of total costs), but highest in the radiation treatment phase for the long-course (€1,974: 60% of total costs). By simultaneously varying treatment time, capacity utilization rates and linear accelerator staff numbers, the base cost fell by 20% for 5-fractions: (€1,660) and 35% for 25-fractions: (€2,354). Conclusions Traditional radiotherapy for rectal cancer is relatively inexpensive. Moreover, significant savings may be achievable through service organization and provision changes. These results suggest that a strong economic argument can be made for expanding the use of radiotherapy in rectal cancer treatment.
Collapse
Affiliation(s)
- Paul Hanly
- School of Business, National College of Ireland, Dublin, Ireland.
| | | | - Máiréad Skally
- Department of Clinical Microbiology, Beaumont Hospital, Dublin, Ireland.
| | - Ciaran O'Neill
- J.E. Cairnes School of Business and Economics, National University of Ireland, Galway, Ireland.
| | - Linda Sharp
- Research Department, National Cancer Registry Ireland, Cork, Ireland.
| |
Collapse
|
10
|
Abstract
Countries, states, and island nations often need forward planning of their radiotherapy services driven by different motives. Countries without radiotherapy services sponsor patients to receive radiotherapy abroad. They often engage professionals for a feasibility study in order to establish whether it would be more cost-beneficial to establish a radiotherapy facility. Countries where radiotherapy services have developed without any central planning, find themselves in situations where many of the available centers are private and thus inaccessible for a majority of patients with limited resources. Government may decide to plan ahead when a significant exodus of cancer patients travel to another country for treatment, thus exposing the failure of the country to provide this medical service for its citizens. In developed countries, the trigger has been the existence of highly visible waiting lists for radiotherapy revealing a shortage of radiotherapy equipment. This paper suggests that there should be a systematic and comprehensive process of long-term planning of radiotherapy services at the national level, taking into account the regulatory infrastructure for radiation protection, planning of centers, equipment, staff, education programs, quality assurance, and sustainability aspects. Realistic budgetary and cost considerations must also be part of the project proposal or business plan.
Collapse
Affiliation(s)
- Eduardo Rosenblatt
- Applied Radiation Biology and Radiotherapy Section, Division of Human Health, International Atomic Energy Agency , Vienna , Austria
| |
Collapse
|
11
|
Zubizarreta EH, Fidarova E, Healy B, Rosenblatt E. Need for radiotherapy in low and middle income countries – the silent crisis continues. Clin Oncol (R Coll Radiol) 2014; 27:107-14. [PMID: 25455407 DOI: 10.1016/j.clon.2014.10.006] [Citation(s) in RCA: 188] [Impact Index Per Article: 18.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2014] [Accepted: 10/17/2014] [Indexed: 12/11/2022]
Abstract
About 57% of the total number of cancer cases occur in low and middle income countries. Radiotherapy is one of the main components of cancer treatment and requires substantial initial investment in infrastructure and training. Many departments continue to have basic facilities and to use simple techniques, while modern technologies have only been installed in big cities in upper-middle income countries. More than 50% of cancer patients requiring radiotherapy in low and middle income countries lack access to treatment. The situation is dramatic in low income countries, where the proportion is higher than 90%. The overall number of additional teletherapy units needed corresponds to about twice the installed capacity in Europe. The figures for different income level groups clearly show the correlation between gross national income per capita and the availability of services. The range of radiotherapy needs currently covered varies from 0% and 3-4% in low income countries in Latin America and Africa up to 59-79% in upper-middle income countries in Europe and Central Asia. The number of additional radiation oncologists, medical physicist, dosimetrists and radiation therapists (RTTs) required to operate additional radiotherapy departments needed is 43 200 professionals. Training and education programmes are not available in every developing country and in many cases the only option is sending trainees abroad, which is not a cost-effective solution. The implementation of adequate local training should be the following step after establishing the first radiotherapy facility in any country. Joint efforts should be made to establish at least one radiotherapy facility in countries where they do not exist, in order to create radiotherapy communities that could be the base for future expansion.
Collapse
Affiliation(s)
| | - E Fidarova
- International Atomic Energy Agency, Vienna, Austria
| | - B Healy
- International Atomic Energy Agency, Vienna, Austria
| | - E Rosenblatt
- International Atomic Energy Agency, Vienna, Austria
| |
Collapse
|
12
|
Dunscombe P, Grau C, Defourny N, Malicki J, Borras JM, Coffey M, Bogusz M, Gasparotto C, Slotman B, Lievens Y, Kokobobo A, Sedlmayer F, Slobina E, De Hertogh O, Hadjieva T, Petera J, Eriksen JG, Jaal J, Bly R, Azria D, Baumann M, Takacsi-Nagy Z, Johannsson J, Cunningham M, Magrini S, Atkocius V, Untereiner M, Pirotta M, Karadjinovic V, Levernes S, Reinfuss M, Trigo ML, Cernea V, Dubinsky P, Barbara Š, Torrecilla JL, Pastoors B, Taylor R, Taylor S. Guidelines for equipment and staffing of radiotherapy facilities in the European countries: Final results of the ESTRO-HERO survey. Radiother Oncol 2014; 112:165-77. [DOI: 10.1016/j.radonc.2014.08.032] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2014] [Accepted: 08/21/2014] [Indexed: 11/26/2022]
|
13
|
Grau C, Defourny N, Malicki J, Dunscombe P, Borras JM, Coffey M, Slotman B, Bogusz M, Gasparotto C, Lievens Y, Kokobobo A, Sedlmayer F, Slobina E, Feyen K, Hadjieva T, Odrazka K, Eriksen JG, Jaal J, Bly R, Chauvet B, Willich N, Polgar C, Johannsson J, Cunningham M, Magrini S, Atkocius V, Untereiner M, Pirotta M, Karadjinovic V, Levernes S, Skladowski K, Trigo ML, Šegedin B, Rodriguez A, Lagerlund M, Pastoors B, Hoskin P, Vaarkamp J, Soler RC. Radiotherapy equipment and departments in the European countries: Final results from the ESTRO-HERO survey. Radiother Oncol 2014; 112:155-64. [DOI: 10.1016/j.radonc.2014.08.029] [Citation(s) in RCA: 124] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2014] [Accepted: 08/21/2014] [Indexed: 11/17/2022]
|
14
|
Reinfuss M, Byrski E, Malicki J. Radiotherapy facilities, equipment, and staffing in Poland: 2005-2011. Rep Pract Oncol Radiother 2013; 18:159-72. [PMID: 24416548 DOI: 10.1016/j.rpor.2013.01.002] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2012] [Accepted: 01/21/2013] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND AND PURPOSE To evaluate the current status of radiotherapy facilities, staffing, and equipment, treatment and patients in Poland for the years 2005-2011 following implementation of the National Cancer Programme. METHODS A survey was sent to the radiotherapy centres in Poland to collect data on available equipment, staffing, and treatments in the years 2005-2011. RESULTS In 2011, 76,000 patients were treated with radiotherapy at 32 centres vs. 63,000 patients at 23 centres in 2005. Number of patients increased by 21%. In 2011, there were 453 radiation oncologists - specialists (1 in 168 patients), 325 medical physicists (1 in 215 patients), and 883 radiotherapy technicians (1 in 86 patients) vs. 320, 188, and 652, respectively, in 2005. The number of linear accelerators increased by 60%, from 70 units in 2005 to 112 in 2011. The current linac/patient ratio in Poland is 1 linac per 678 patients. Waiting times from diagnosis to the start of treatment has decreased. CONCLUSION Compared to 2005, there are more treatment facilities, more and better equipment (linacs), and more cancer care specialists. There are still large differences between the 16 Polish provinces in terms of equipment availability and ease of access to treatment. However, radiotherapy services in Poland have improved dramatically since the year 2005.
Collapse
Affiliation(s)
- Marian Reinfuss
- Center of Oncology - Maria Sklodowska-Curie Memorial Institute, Krakow, Poland
| | - Edward Byrski
- Center of Oncology - Maria Sklodowska-Curie Memorial Institute, Krakow, Poland
| | - Julian Malicki
- Medical Physics Department, Greater Poland Cancer Centre, Poland ; Electroradiology Department, University of Medical Sciences, Poznan, Poland ; Medical Physics Department, Adam Mickiewicz University, Poznan, Poland
| |
Collapse
|
15
|
Leung HWC, Chan ALF. Direct medical cost of radiation therapy for cancer patients in Taiwan. Health (London) 2013. [DOI: 10.4236/health.2013.56131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
16
|
van Loon J, Grutters J, Macbeth F. Evaluation of novel radiotherapy technologies: what evidence is needed to assess their clinical and cost effectiveness, and how should we get it? Lancet Oncol 2012; 13:e169-77. [DOI: 10.1016/s1470-2045(11)70379-5] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
17
|
Pommier P, Lievens Y, Feschet F, Borras JM, Baron MH, Shtiliyanova A, Pijls-Johannesma M. Simulating demand for innovative radiotherapies: An illustrative model based on carbon ion and proton radiotherapy. Radiother Oncol 2010; 96:243-9. [DOI: 10.1016/j.radonc.2010.04.010] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2009] [Revised: 03/30/2010] [Accepted: 04/05/2010] [Indexed: 10/19/2022]
|
18
|
Ploquin N, Dunscombe P. A cost-outcome analysis of Image-Guided Patient Repositioning in the radiation treatment of cancer of the prostate. Radiother Oncol 2009; 93:25-31. [PMID: 19409635 DOI: 10.1016/j.radonc.2009.03.023] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2008] [Revised: 03/22/2009] [Accepted: 03/31/2009] [Indexed: 10/20/2022]
Abstract
BACKGROUND AND PURPOSE With Image-Guided Radiation Therapy (IGRT) rapidly gaining acceptance in the clinic it is timely to commence an assessment of its potential outcome benefit versus costs. MATERIALS AND METHODS Using Activity-Based Costing we have calculated the incremental cost of adding Image-Guided Patient Repositioning (IGPR), a significant component of IGRT, to both Intensity-Modulated Radiation Therapy (IMRT) and Three-Dimensional Conformal Radiation Therapy (3DCRT) for prostate cancer. The dosimetric outcome benefit resulting from the implementation of IGPR is estimated from a publication describing the improvement in set-up accuracy using each of four correction protocols. In our study outcome is quantified using a metric based on the Equivalent Uniform Dose. Our discussion is limited to image-guided corrective translations of the patient and does not specifically address margin reduction, rotations, organ deformation or major equipment failure modes, all of which are significant additional justifications for implementing an IGRT program. RESULTS Image guidance used solely for translational patient repositioning for prostate cancer adds costs with relatively little improvement in dosimetric quality. Full exploitation of the potential of IGRT, particularly through margin reduction, can be expected to result in a reduction in the cost-outcome ratios reported here. CONCLUSIONS IMRT benefits more than 3DCRT from IGPR with the Weekly Shrinking Action Level approach yielding the lowest cost-outcome ratio.
Collapse
Affiliation(s)
- Nicolas Ploquin
- Tom Baker Cancer Centre, Department of Medical Physics, Alta., Canada.
| | | |
Collapse
|
19
|
|
20
|
The cost of radiation therapy. Radiother Oncol 2008; 86:217-23. [DOI: 10.1016/j.radonc.2008.01.005] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2007] [Revised: 01/06/2008] [Accepted: 01/06/2008] [Indexed: 11/21/2022]
|
21
|
White L, Beckingham E, Calman F, Deehan C. Extended hours working in radiotherapy in the UK. Clin Oncol (R Coll Radiol) 2007; 19:213-22. [PMID: 17433966 DOI: 10.1016/j.clon.2007.01.442] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2006] [Revised: 01/06/2007] [Accepted: 01/25/2007] [Indexed: 11/21/2022]
Abstract
AIMS To analyse extended hours working patterns within UK cancer centres and to assess alternatives to the normal 9.00 am to 5.00 pm working day. MATERIALS AND METHODS Questionnaires were sent to 62 radiotherapy managers in June and July 2005 to survey where extended hours working had been implemented, the objectives for using a longer working day and how departments organised their service issues, including staffing levels, costs and patients. This was followed by visits to six departments that were working extended hours. A second questionnaire sent to 60 radiotherapy physics managers in September 2005 requested information for the hours of daily, monthly and annual megavoltage machine servicing and quality assurance (QA). A third questionnaire was distributed to all radiotherapy outpatients from four departments who attended on a single day of survey in 2005. It looked at patient preference for treatment hours. RESULTS In total, 57 (92%) radiotherapy managers responded. Thirty-one departments (55%) were working extended hours, 22 (39%) had short-term experience and three (5%) departments had no experience. Increasing capacity to reduce waiting lists was the main reason for working extended hours. The additional hours were predominantly worked by radiographers, with little or no support from the other department disciplines. The servicing and QA spreadsheet was returned by 53% (n=32) of physicists. The average amount of servicing and Quality Assurance (QA) work being scheduled out of hours in each department was 35% (0-100%). The patient questionnaire was completed by 470 patients. When asked if patients would want to come to a reasonable appointment time outside of the normal working day, 29% (n=136) said 'yes' and 12% (n=55) were unsure. CONCLUSION It was concluded that two shifts covering an 11.5 h working day is a robust alternative to the normal working day, taking into consideration efficient use of radiographers and patient preference for out of hours appointments.
Collapse
Affiliation(s)
- L White
- Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK
| | | | | | | |
Collapse
|
22
|
Abstract
In order to support adoption and dissemination into clinical practice of innovative treatment strategies, being almost by definition more expensive than the corresponding standard treatments, an appropriate reimbursement is a prerequisite. This article describes different possible financing systems in the context of technological advances in radiation oncology and analyses if and how the reimbursement issue has been tackled in European radiotherapy centres.
Collapse
Affiliation(s)
- Y Lievens
- Département de Radiothérapie Oncologique, Universitaire Ziekenhuizen Leuven, Herestraat 49, 3000 Leuven, Belgique.
| |
Collapse
|
23
|
Probst H, Griffiths S. Moving to a High-tech Approach to the Irradiation of Early Breast Cancer: Is It Possible to Balance Efficacy, Morbidity and Resource Use? Clin Oncol (R Coll Radiol) 2006; 18:268-75. [PMID: 16605058 DOI: 10.1016/j.clon.2005.11.009] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
There is substantial evidence documenting the potential morbidity associated with radiotherapy in early breast cancer. An appraisal of current standard radiation practice is therefore necessary, given that women are surviving longer, have an improved quality of life, and are overcoming subsequent side-effects caused by postoperative irradiation. New technology allows the application of more complex approaches. This discussion paper considers some of the benefits of the widespread use of new complex approaches, such as intensity-modulated radiotherapy (IMRT) in the light of staffing and equipment shortfalls, and possible consequences on waiting times for treatment. The discussion is considered under the following themes: (1) which women with breast cancer benefit from complex treatment approaches? (2) What is the role of treatment accuracy in limiting morbidity? And (3) what is the potential effect of complex breast irradiation approaches on service delivery? In the UK, and globally, many departments are struggling to meet waiting-time guidelines. The use of more complex approaches for breast irradiation may increase this difficulty. However, a number of simple technical changes can be used to enhance efficacy and reduce levels of normal tissue morbidity. A sub-set of women who are at greatest risk from normal tissue morbidity or reduced cosmesis should be accurately defined in order to allow departments to plan their treatment strategies with optimal use of resources.
Collapse
Affiliation(s)
- H Probst
- Faculty of Health and Wellbeing, Sheffield Hallam University, Sheffield, UK.
| | | |
Collapse
|
24
|
Barbera L, Walker H, Foroudi F, Tyldesley S, Mackillop W. Estimating the benefit and cost of radiotherapy for lung cancer. Int J Technol Assess Health Care 2004; 20:545-51. [PMID: 15609808 DOI: 10.1017/s0266462304001485] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Purpose: To estimate the benefit and cost of using radiotherapy (RT) in the initial management of lung cancer in the general population.Methods: We identified indications for RT in the initial management of small cell and non–small cell lung cancer through a review of the literature. The proportion of patients with each specific indication for treatment was determined using epidemiological observations from cancer registry data and from the literature. We estimated the benefit gained from RT use for each indication in the model using values published in the literature. We estimated the cost of RT for each indication using published Canadian data. The total benefit and cost was calculated for all indications combined. Results are reported in 2001 Canadian dollars.Results: The mean benefit was 7 months of survival for each lung cancer patient treated with curative intent and 3 months of symptom control for each patient treated with palliative intent. The average cost was $9,881 per life year gained and $13,938 per year of symptom control gained. Sensitivity analysis revealed values between $7,905 and $19,762 per year of survival gain and between $10,368 and $27,875 per year of symptom control gained.Conclusions: Using RT in the initial management of lung cancer can provide considerable gains in survival and symptom control. The cost of RT for the initial management of lung cancer is inexpensive compared with a common cut off of $50,000 per life year gained.
Collapse
Affiliation(s)
- Lisa Barbera
- Department of Radiation Oncology, Toronto Sunnybrook Regional Cancer Centre, Ontario, Canada.
| | | | | | | | | |
Collapse
|
25
|
Van Der Giessen PH, Alert J, Badri C, Bistrovic M, Deshpande D, Kardamakis D, Van Der Merwe D, Da Motta N, Pinillos L, Sajjad R, Tian Y, Levin V. Multinational assessment of some operational costs of teletherapy. Radiother Oncol 2004; 71:347-55. [PMID: 15172152 DOI: 10.1016/j.radonc.2004.02.021] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2003] [Revised: 01/06/2004] [Accepted: 02/25/2004] [Indexed: 11/16/2022]
Abstract
BACKGROUND AND PURPOSE Decisions in planning radiotherapy facilities in countries with limited financial resources require information on economic factors to make provision for sustainability. This study aims at acquiring data on some of these factors involved in delivery of teletherapy in 11 countries of different economic status. PATIENTS AND METHODS Representatives of three European, one African, three Latin American and four Asian countries, were identified from radiation oncology institutions that operated both cobalt and linac teletherapy machines. Productivity data were prospectively collected for the year 2002. A detailed log was recorded for each machine over an arbitrary two-week period. Data on quality assurance (QA), maintenance, the capital costs of each machine, and the source replacement costs for the cobalt units were also recorded. RESULTS Both linear accelerators and cobalt machines treat more than 10,000 fractions per year per machine with 2.5 and 2.3 fields per fraction, respectively. The capital costs of the machines vary considerably, with a factor of more than 10 for linear accelerators. Cobalt sources show a huge variation in price. The median costs of QA and maintenance of a linac was US$ 41,000 compared to US$ 6000 for cobalt machines. This results for the economic factors considered in median costs per fraction of US$ 11.02 for linear accelerators and US$ 4.87 for cobalt machines. These figures do not include the costs for physicians. CONCLUSIONS The variation of the costs per fraction is more due to the result of differences in machine usage and costs of equipment than of national economic status. A treatment fraction on a linac with functionality comparable to cobalt, costs 50% more than cobalt therapy. This project shows that it is possible to collect data on economic factors prospectively as well as retrospectively.
Collapse
|
26
|
Lorenz KA, Asch SM, Rosenfeld KE, Liu H, Ettner SL. Hospice Admission Practices: Where Does Hospice Fit in the Continuum of Care? J Am Geriatr Soc 2004; 52:725-30. [PMID: 15086652 DOI: 10.1111/j.1532-5415.2004.52209.x] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
OBJECTIVES To evaluate selected hospice admission practices that could represent barriers to hospice use and the association between these admission practices and organizational characteristics. DESIGN From December 1999 to March 2000, hospices were surveyed about selected admission practices, and their responses were linked to the 1999 California Office of Statewide Health Planning and Development's Home and Hospice Care Survey that describes organizational characteristics of California hospices. SETTING California statewide. PARTICIPANTS One hundred of 149 (67%) operational licensed hospices. MEASUREMENTS Whether hospices admit patients who lack a caregiver; would not forgo hospital admissions; or are receiving total parenteral nutrition (TPN), tube feedings, radiotherapy, chemotherapy, or transfusions. RESULTS Sixty-three percent of hospices restricted admission on at least one criterion. A significant minority of hospices would not admit patients lacking a caregiver (26%). Patients unwilling to forgo hospitalization could not be admitted to 29% of hospices. Receipt of complex medical care, including TPN (38%), tube feedings (3%), transfusions (25%), radiotherapy (36%), and chemotherapy (48%), precluded admission. Larger program size was significantly associated with a lower likelihood of all admission practices except restricting the admission of patients receiving TPN or tube feedings. Hospice programs that were part of a hospice chain were less likely to restrict the admission of patients using TPN, radiotherapy, or chemotherapy than were freestanding programs. CONCLUSION Patients who are receiving complex palliative treatments could face barriers to hospice enrollment. Policy makers should consider the clinical capacity of hospice providers in efforts to improve access to palliative care and more closely incorporate palliation with other healthcare services.
Collapse
Affiliation(s)
- Karl A Lorenz
- Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA.
| | | | | | | | | |
Collapse
|
27
|
Abstract
Against a background of increasing demand for radiotherapy equipment, this study was undertaken to investigate options for equipment procurement, in particular to compare purchase with lease. The perceived advantages of lease are that equipment can be acquired within budget and cashflow constraints, with relatively low amounts of cash leaving the NHS in the first year, avoiding the necessity of capitalizing the equipment and providing protection against the risk of obsolescence associated with high technology equipment. The perceived disadvantages of leasing are that the Trust does not own the equipment, leasing can be more expensive in revenue terms, the tender process is extended and there may be lease conditions to be met, which may be costly and/or restrictive. There are also a number of technical considerations involved in the leasing of radiotherapy equipment that influence the financial analysis and practical operation of the radiotherapy service. The technical considerations include servicing and planned preventative maintenance, upgrades, spare parts, subsequent purchase of "add ons", modification of equipment, research and development work, commencement of the lease period, return of equipment at the end of the lease period and negotiations at the end of the lease period. A study from Raigmore Hospital, Inverness is described, which involves the procurement of new, state-of-the-art radiotherapy equipment. This provides an overview of the procurement process, including a summary of the advantages and disadvantages of leasing, with the figures from the financial analysis presented and explained. In addition, a detailed description is given of the technical considerations to be taken into account in the financial analysis and negotiation of any lease contract.
Collapse
Affiliation(s)
- A Nisbet
- Department of Medical Physics and Bio-Engineering, Raigmore Hospital, Old Perth Road, Inverness IV2 3UJ, UK
| | | |
Collapse
|
28
|
Dunscombe P, Roberts G. Radiotherapy service delivery models for a dispersed patient population. Clin Oncol (R Coll Radiol) 2001; 13:29-37. [PMID: 11292133 DOI: 10.1053/clon.2001.9211] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Access to health care interventions can be impeded when significant patient travel is required. In this economic evaluation we compare, from a societal perspective, three scenarios for the delivery of radiation treatment to an idealized population of 1,600 patients distributed between two urban nodes (1,200 + 400 patients each) separated by up to 500 km. As it is implicitly assumed that the clinical outcome for those patients who access the system is independent of the service delivery model, this study constitutes a cost minimization analysis from a societal perspective. The costs to the health care system are based on an activity costing model developed by us and consistent with recent Canadian studies. The costs to the patient are approximated by a formula that includes direct costs (travel and accommodation) and indirect (time) costs, with the latter based on a human capital approach. A sensitivity analysis has been performed to confirm the robustness of our conclusions both to uncertainties in the input data and to the inclusion of time costs, the estimation of which remains controversial. From a societal cost perspective only, we show that outreach radiotherapy (central comprehensive facility and satellite) is the economically superior service delivery model for separations between 30 km and 170 km. Beyond 170 km, a fully decentralized service would be warranted if the only consideration were societal economic advantage.
Collapse
Affiliation(s)
- P Dunscombe
- Northeastern Ontario Regional Cancer Centre, Sudbury, Canada.
| | | |
Collapse
|
29
|
Dunscombe P, Samant R, Roberts G. A cost-outcome analysis of adjuvant postmastectomy locoregional radiotherapy in premenopausal node-positive breast cancer patients. Int J Radiat Oncol Biol Phys 2000; 48:977-82. [PMID: 11072153 DOI: 10.1016/s0360-3016(00)00672-6] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
PURPOSE To calculate cost-effectiveness and cost-utility ratios for adjuvant postmastectomy locoregional radiotherapy in premenopausal node-positive breast cancer patients and to place these ratios in the context of generally accepted medical expenditures. MATERIALS AND METHODS A spreadsheet-based activity costing model using 1997 Canadian (cdn) capital, operating, and administrative costs has been used to identify, from the institutional perspective, the incremental cost of adding radiotherapy to surgery and chemotherapy for this group of patients. Outcome data were derived from two recently published clinical trials and were converted to discounted incremental life years and quality-adjusted life years gained. Recommended health economics principles were employed in the quantification of both costs and outcomes, and a sensitivity analysis was performed. Three referenced publications provide a context within which to evaluate the calculated cost-effectiveness and cost-utility ratios. RESULTS The incremental cost of adjuvant radiotherapy for this group of patients is calculated to be approximately $7,000cdn in 1997 Canadian dollars and in the Canadian socialized health-care environment. Based on published work the discounted incremental outcome benefit is calculated to be 0.5 life years or 0.45 quality-adjusted life years at ten years. Thus, cost effectiveness and cost-utility ratios are estimated to be $14,000cdn and $15,600cdn, respectively. CONCLUSION Within the context of generally accepted medical expenditures, adjuvant postmastectomy locoregional radiotherapy for premenopausal node-positive breast cancer patients would be regarded as a cost-effective treatment strategy.
Collapse
Affiliation(s)
- P Dunscombe
- Northeastern Ontario Regional Cancer Centre, Sudbury, Ontario, Canada.
| | | | | |
Collapse
|